Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1

Interventions

Methotrexate 10Cyclophosphamide 10Cytarabine 9merphos 7Vincristine 7Asparaginase 7Specimen Handling 6Methylprednisolone 6Hydrocortisone 6Daunorubicin 6pegaspargase 5fludarabine phosphate 5Prednisone 5Mercaptopurine 5fludarabine 4calaspargase pegol 4Whole-Body Irradiation 4Prednisolone 4Mycophenolic Acid 4Leucovorin 4Filgrastim 4Dexamethasone 4Busulfan 4Biopsy 4prednylidene 3dexamethasone acetate 3dexamethasone 21-phosphate 3deltacortene 3azathiopurine 3auricularum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Leukemia, Biphenotypic, Acute × Liposomes × Clear all
NCT05320380 2023-09-01

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Children's Oncology Group

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡